Company Profile
Chemomab Therapeutics Stock Price, News & Analysis
- Ticker:
- CMMB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Israel
Stock performance
1.42 USD (+4.41%)
Close
Last updated: July 27, 2026
12.5M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, CMMB closed up 4.41% at $1.42. No new same-company headline was identified in the current news window.
Company overview
Business overview
Chemomab Therapeutics is a biotechnology company focused on fibrosis and inflammatory disease biology. Its story is centered on targeting tough chronic conditions where disease-modifying therapies are still needed.
Geographic Base and Sector Classification
Chemomab is headquartered in Israel and listed on NASDAQ. It sits in specialty immunology and fibrosis biotechnology.
Business Model Characteristics
The company depends on clinical validation, translational confidence, and capital discipline while advancing a narrow pipeline. Investors usually watch early data and proof-of-concept.
Position Within the Biotechnology Landscape
Chemomab occupies a niche fibrosis-immunology position within biotech. The stock is sensitive to whether its biology can show meaningful clinical effect.
Future catalysts
For Chemomab Therapeutics, the near-term story still runs through IBD-related and PRO-C3. Recent commentary puts the focus on “In an oral presentation earlier this month at Digestive Disease Week® 2026 and in three upcoming presentations at the 2026 EASL Congress, we unveiled new analyses based on.... That leaves the stock tied to whether the next milestone lands on schedule.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
- 02
- 03
- 04
- 05
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
AVTX · Source: Avalo Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Chemomab Therapeutics (CMMB)?
Chemomab Therapeutics (CMMB) most recently closed at 1.42 USD, a +4.41% move versus the previous session.
What is the market cap of Chemomab Therapeutics (CMMB)?
Chemomab Therapeutics currently has a market capitalization of 12.5M USD on BioPharmSignal.
What does Chemomab Therapeutics do?
Chemomab Therapeutics is a biotechnology company focused on fibrosis and inflammatory disease biology. Its story is centered on targeting tough chronic conditions where disease-modifying therapies are still needed.
On which exchange is CMMB stock listed?
Chemomab Therapeutics (CMMB) is associated with NASDAQ, Israel, Biopharma.
What is PRO-C3?
For Chemomab Therapeutics, the near-term story still runs through IBD-related and PRO-C3.
Which conditions is Chemomab Therapeutics targeting with PRO-C3?
For Chemomab Therapeutics, the near-term story still runs through IBD-related and PRO-C3.
How does Chemomab Therapeutics describe recent progress with PRO-C3?
For Chemomab Therapeutics, the near-term story still runs through IBD-related and PRO-C3.
What is Chemomab?
Chemomab Therapeutics is a biotechnology company focused on fibrosis and inflammatory disease biology.